BioInsights - Vol 6 Issue 8

CELL & GENE THERAPY INSIGHTS

September 2020 Issue

Vol 6 Issue 8

Download PDF

Featuring

Issue Spotlight: Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture
Focus: Biopreservation and cold chain management
Other articles
Webinars

SPOTLIGHT

Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture
Jan Thirkettle
Guest Editor:
Jan Thirkettle, Chief Executive Officer at Transine Therapeutics

Foreword

Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture

Scaling up/out: cost-effective and robust transitioning through the clinic to commercial manufacture

Jan Thirkettle
29 September 2020
Read

Expert Insight

Scale-up vs scale-out: evaluating manufacturing scalability of CAR T cell therapy using process simulation tools

Scale-up vs scale-out: evaluating manufacturing scalability of CAR T cell therapy using process simulation tools

A Katragadda, I Karimi, X Wang
3 September 2020
Read

Innovator Insight

Scalable and efficient AAV production process with new Fibro chromatography technology

Scalable and efficient AAV production process with new Fibro chromatography technology

L Adamson-Small, M Lundgren, P Guterstam
30 September 2020
Read

Commentary

The power of small: success of small academic/healthcare units within the cell & gene therapy industry

The power of small: success of small academic/healthcare units within the cell & gene therapy industry

Benjamin Weil, Owen Bain
24 September 2020
Read
Small labels, big challenges: solutions for advanced therapy labeling

Small labels, big challenges: solutions for advanced therapy labeling

Heidi Hagen, Christophe Suchet
21 September 2020
Read

Interview

Delivering cell and gene therapies: evolving logistics considerations

Delivering cell and gene therapies: evolving logistics considerations

Adrian Lee-Mohan, David Murphy
29 September 2020
Read
A necessary transition: why viral vector production for gene therapy needs to evolve

A necessary transition: why viral vector production for gene therapy needs to evolve

29 September 2020
Read
Driving NK cell therapy manufacture to commercial scale

Driving NK cell therapy manufacture to commercial scale

Leonard Sender
23 September 2020
Read

Podcast

Delivering cell and gene therapies: evolving logistics considerations - Podcast

Delivering cell and gene therapies: evolving logistics considerations - Podcast

Adrian Lee-Mohan, David Murphy
29 September 2020
Listen

Expert Roundtable Video

Expert Roundtable: getting a gene therapy product to market: pitfalls and how to prevent them

Expert Roundtable: getting a gene therapy product to market: pitfalls and how to prevent them

H Brahmbhatt, T Guarinoni, E Simmons
21 September 2020
Watch

Expert Roundtable

Expert Roundtable: getting a gene therapy product to market: pitfalls and how to prevent them

Expert Roundtable: getting a gene therapy product to market: pitfalls and how to prevent them

H Brahmbhatt, T Guarinoni, E Simmons
29 September 2020
Read

FastFacts

TESSA technology: a new paradigm in AAV manufacturing

TESSA technology: a new paradigm in AAV manufacturing

Ryan Cawood
1 October 2020
Read

Supply Chain FOCUS

Biopreservation and cold chain management

Interview

How will COVID-19 impact the cord blood banking sector?

How will COVID-19 impact the cord blood banking sector?

Wouter Van't Hof
5 June 2020
Read

Expert Insight

The supply chain: key considerations for biological starting material for ATMPs production

The supply chain: key considerations for biological starting material for ATMPs production

Elisabet Aguilar
22 September 2020
Read
Utilization of risk-based approach to characterize starting material for autologous CAR-T manufacturing

Utilization of risk-based approach to characterize starting material for autologous CAR-T manufacturing

Jean Stanton
8 September 2020
Read

Innovator Insight

Biopreservation and cold chain biologistics risk points in the cell and gene therapy workflow

Biopreservation and cold chain biologistics risk points in the cell and gene therapy workflow

Todd CJ Berard, Aby J Mathew
3 November 2020
Read

Journal articles

Expert Insight

Using serum-free media to streamline and optimize CAR T-cell manufacturing workflows

Using serum-free media to streamline and optimize CAR T-cell manufacturing workflows

Chengkang (CK) Zhang, Amber Jones
10 September 2020
Read

Perspective

Regulatory perspective on ATMPs: device combinations

Regulatory perspective on ATMPs: device combinations

Ilona Reischl, Stefan Strasser
13 August 2020
Read
Advanced therapy regulation in the UK: what might the future hold post-Brexit?

Advanced therapy regulation in the UK: what might the future hold post-Brexit?

Patrick Ginty
18 September 2020
Read

Interview

EMA CAT perspective: the European Union regulatory landscape for ATMPs

EMA CAT perspective: the European Union regulatory landscape for ATMPs

Martina Schüssler-Lenz
22 September 2020
Read

Webinars